Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management

Gastroenterology

Volumn 145, Issue 3, 2013, Pages 521-536

  Eaton, John E ^a   Talwalkar, Jayant A ^a   Lazaridis, Konstantinos N ^a   Gores, Gregory J ^a   Lindor, Keith D ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Autoimmune Disease; Cholangiocarcinoma; Cholestatic Liver Disease; Inflammatory Bowel Disease

Indexed keywords

ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; AZATHIOPRINE; CELL ADHESION MOLECULE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; OBETICHOLIC ACID; PENTOXIFYLLINE; RETINOIC ACID; TACROLIMUS; TOFACITINIB; URSODEOXYCHOLIC ACID; USTEKINUMAB; VEDOLIZUMAB;

ALKALINE PHOSPHATASE BLOOD LEVEL; BILE DUCT CARCINOMA; CANCER RISK; CHEMOPROPHYLAXIS; CHOLANGIOGRAPHY; COLORECTAL TUMOR; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CYTOLOGY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MODEL; ENDOSCOPIC THERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; INNATE IMMUNITY; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LYMPHOCYTE; MOLECULAR PATHOLOGY; NEOPLASM; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; T LYMPHOCYTE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 84883150093     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.06.052     Document Type: Review

References (169)

1. J.E. Berdal, J. Ebbesen, and A. Rydning Incidence and prevalence of autoimmune liver diseases (in Norwegian) Tidsskrift Nor Laegeforen 118 1998 4517 4519
2. B. Lindkvist, M. Benito de Valle, and B. Gullberg Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden Hepatology 52 2010 571 577
3. K. Bambha, W.R. Kim, and J. Talwalkar Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community Gastroenterology 125 2003 1364 1369
4. G.G. Kaplan, K.B. Laupland, and D. Butzner The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis Am J Gastroenterol 102 2007 1042 1049
5. N.A. Molodecky, H. Kareemi, and R. Parab Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis Hepatology 53 2011 1590 1599
6. A. Escorsell, A. Pares, and J. Rodes Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver J Hepatol 21 1994 787 791
7. T.L. Ang, K.M. Fock, and T.M. Ng Clinical profile of primary sclerosing cholangitis in Singapore J Gastroenterol Hepatol 17 2002 908 913
8. M.K. Porayko, R.H. Wiesner, and N.F. LaRusso Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease Gastroenterology 98 1990 1594 1602
9. U. Broome, R. Olsson, and L. Loof Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis Gut 38 1996 610 615
10. C.Y. Ponsioen, S.M. Vrouenraets, and W. Prawirodirdjo Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population Gut 51 2002 562 566
11. B.E. Wellge, M. Sterneck, and A. Teufel Pregnancy in primary sclerosing cholangitis Gut 60 2011 1117 1121
12. R. Chapman, J. Fevery, and A. Kalloo Diagnosis and management of primary sclerosing cholangitis Hepatology 51 2010 660 678
13. R. Olsson, A. Danielsson, and G. Jarnerot Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis Gastroenterology 100 1991 1319 1323
14. A. Bergquist, G. Lindberg, and S. Saarinen Increased prevalence of primary sclerosing cholangitis among first-degree relatives J Hepatol 42 2005 252 256
15. S.A. Mitchell, M. Thyssen, and T.R. Orchard Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study Gut 51 2002 567 573
16. W.R. Kim, T.M. Therneau, and R.H. Wiesner A revised natural history model for primary sclerosing cholangitis Mayo Clin Proc 75 2000 688 694
17. Y.M. Lee, and M.M. Kaplan Management of primary sclerosing cholangitis Am J Gastroenterol 97 2002 528 534
18. P.P. Stanich, E. Bjornsson, and A.A. Gossard Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis Dig Liver Dis 43 2011 309 313
19. P. Angulo, J.B. Peter, and M.E. Gershwin Serum autoantibodies in patients with primary sclerosing cholangitis J Hepatol 32 2000 182 187
20. R.L. MacCarty, N.F. LaRusso, and R.H. Wiesner Primary sclerosing cholangitis: findings on cholangiography and pancreatography Radiology 149 1983 39 44
21. M. Dave, B.J. Elmunzer, and B.A. Dwamena Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography Radiology 256 2010 387 396
22. E. Kaltenthaler, Y.B. Vergel, and J. Chilcott A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography Health Technol Assess 8 2004 iii 1-89
23. J.A. Talwalkar, P. Angulo, and C.D. Johnson Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis Hepatology 40 2004 39 45
24. P.J. Scheuer Ludwig Symposium on biliary disorders - part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis Mayo Clinic Proc 73 1998 179 183
25. K.W. Burak, P. Angulo, and K.D. Lindor Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 98 2003 1155 1158
26. J.L.N. Ludwig, and R.H. Wiesner Primary sclerosing cholangitis. Contemporary issues in surgical pathology: liver pathology 1986 Churchill Livingstone New York 193 213
27. C. Corpechot, A. El Naggar, and A. Poujol-Robert Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC Hepatology 43 2006 1118 1124
28. E. Kojima, K. Kimura, and Y. Noda Autoimmune pancreatitis and multiple bile duct strictures treated effectively with steroid J Gastroenterol 38 2003 603 607
29. E. Bjornsson, S.T. Chari, and T.C. Smyrk Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature Hepatology 45 2007 1547 1554
30. A. Ghazale, S.T. Chari, and L. Zhang Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy Gastroenterology 134 2008 706 715
31. H. Ohara, K. Okazaki, and H. Tsubouchi Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012 J Hepatobiliary Pancreat Sci 19 2012 536 542
32. E. Bjornsson, S. Chari, and M. Silveira Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy Am J Ther 18 2011 198 205
33. F.D. Mendes, R. Jorgensen, and J. Keach Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis Am J Gastroenterol 101 2006 2070 2075
34. L. Zhang, J.T. Lewis, and S.C. Abraham IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis Am J Surg Pathol 34 2010 88 94
35. A.M. Oseini, R. Chaiteerakij, and A.M. Shire Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma Hepatology 54 2011 940 948
36. R.C. Verdonk, G. Dijkstra, and E.B. Haagsma Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease Am J Transplant 6 2006 1422 1429
37. E. Sinakos, S. Samuel, and F. Enders inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship Inflamm Bowel Dis 19 2013 1004 1009
38. E.V. Loftus Jr., G.C. Harewood, and C.G. Loftus PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis Gut 54 2005 91 96
39. K. Boonstra, K.J. van Erpecum, and K.M. van Nieuwkerk Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease Inflamm Bowel Dis 18 2012 2270 2276
40. M. Joo, P. Abreu-e-Lima, and F. Farraye Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study Am J Surg Pathol 33 2009 854 862
41. K.K. Jorgensen, K. Grzyb, and K.E. Lundin Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients Inflamm Bowel Dis 18 2012 536 545
42. R.M. Soetikno, O.S. Lin, and P.A. Heidenreich Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis Gastrointest Endosc 56 2002 48 54
43. C. Penna, R. Dozois, and W. Tremaine Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis Gut 38 1996 234 239
44. R.H. Wiesner, N.F. LaRusso, and R.R. Dozois Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis Gastroenterology 90 1986 316 322
45. R.W. Chapman, B.A. Arborgh, and J.M. Rhodes Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology Gut 21 1980 870 877
46. J. Fevery, L. Henckaerts, and R. Van Oirbeek Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study Liver Int 32 2012 214 222
47. L. Marelli, E. Xirouchakis, and G. Kalambokis Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 60 2011 1224 1228
48. U. Navaneethan, P.G. Venkatesh, and S. Mukewar Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis Clin Gastroenterol Hepatol 10 2012 540 546
49. P. Angulo, Y. Maor-Kendler, and K.D. Lindor Small-duct primary sclerosing cholangitis: a long-term follow-up study Hepatology 35 2002 1494 1500
50. E. Bjornsson, R. Olsson, and A. Bergquist The natural history of small-duct primary sclerosing cholangitis Gastroenterology 134 2008 975 980
51. E. Bjornsson, K.M. Boberg, and S. Cullen Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis Gut 51 2002 731 735
52. T. Al-Chalabi, B.C. Portmann, and W. Bernal Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival Aliment Pharmacol Ther 28 2008 209 220
53. M. Kaya, P. Angulo, and K.D. Lindor Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system J Hepatol 33 2000 537 542
54. R. Abdalian, P. Dhar, and K. Jhaveri Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging Hepatology 47 2008 949 957
55. P.J. Trivedi, and G.M. Hirschfield Review article: overlap syndromes and autoimmune liver disease Aliment Pharmacol Ther 36 2012 517 533
56. K.M. Boberg, R.W. Chapman, and G.M. Hirschfield Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue J Hepatol 54 2011 374 385
57. M.J. Pollheimer, E. Halilbasic, and P. Fickert Pathogenesis of primary sclerosing cholangitis Best Pract Res Clin Gastroenterol 25 2011 727 739
58. A. Spurkland, S. Saarinen, and K.M. Boberg HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations Tissue Antigens 53 1999 459 469
59. J.M. Farrant, D.G. Doherty, and P.T. Donaldson Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis Hepatology 16 1992 390 395
60. W.Z. Mehal, Y.M. Lo, and B.P. Wordsworth HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis Gastroenterology 106 1994 160 167
61. O. Olerup, R. Olsson, and R. Hultcrantz HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis Gastroenterology 108 1995 870 878
62. T.H. Karlsen, A. Franke, and E. Melum Genome-wide association analysis in primary sclerosing cholangitis Gastroenterology 138 2010 1102 1111
63. E. Melum, A. Franke, and C. Schramm Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci Nat Genet 43 2011 17 19
64. J.Z. Liu, J.R. Hov, and T. Folseraas Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis Nat Genet 45 2013 670 675
65. C.A. O'Mahony, and J.M. Vierling Etiopathogenesis of primary sclerosing cholangitis Semin Liver Dis 26 2006 3 21
66. S.N. Lichtman, and R.B. Sartor Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats Immunol Res 10 1991 528 531
67. S. Yamada, M. Ishii, and L.S. Liang Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats J Gastroenterol 29 1994 631 636
68. M.J. Pollheimer, M. Trauner, and P. Fickert Will we ever model PSC? - "it's hard to be a PSC model!" Clin Res Hepatol Gastroenterol 35 2011 792 804
69. K.R. Palmer, B.I. Duerden, and C.D. Holdsworth Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery Gut 21 1980 851 854
70. B. Terjung, and U. Spengler Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"? Clin Rev Allergy Immunol 36 2009 40 51
71. B. Terjung, J. Sohne, and B. Lechtenberg p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ Gut 59 2010 808 816
72. M. Farkkila, A.L. Karvonen, and H. Nurmi Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial Hepatology 40 2004 1379 1386
73. M.G. Silveira, N.J. Torok, and A.A. Gossard Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study Am J Gastroenterol 104 2009 83 88
74. P. Sheth, N. Delos Santos, and A. Seth Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism Am J Physiol Gastrointest Liver Physiol 293 2007 G308 G318
75. S. Guo, R. Al-Sadi, and H.M. Said Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14 Am J Pathol 182 2013 375 387
76. P. Fickert, A. Fuchsbichler, and M. Wagner Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice Gastroenterology 127 2004 261 274
77. P. Fickert, A. Fuchsbichler, and H.U. Marschall Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice Am J Pathol 168 2006 410 422
78. T. Mueller, C. Beutler, and A.H. Pico Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis Liver Int 31 2011 1574 1588
79. A.E. Medvedev, I. Sabroe, and J.D. Hasday Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease J Endotoxin Res 12 2006 133 150
80. J. Katt, D. Schwinge, and T. Schoknecht Increased Th17 response to pathogen stimulation in patients with primary sclerosing cholangitis Hepatology 2013 Apr 8 [Epub ahead of print]
81. J. Pohl, A. Ring, and W. Stremmel The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis Eur J Gastroenterol Hepatol 18 2006 69 74
82. J.H. Aron, and C.L. Bowlus The immunobiology of primary sclerosing cholangitis Semin Immunopathol 31 2009 383 397
83. A.T. Borchers, S. Shimoda, and C. Bowlus Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis Semin Immunopathol 31 2009 309 322
84. K.J. Hillan, K.E. Hagler, and R.N. MacSween Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease Liver 19 1999 509 518
85. A.J. Grant, P.F. Lalor, and S.G. Hubscher MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease) Hepatology 33 2001 1065 1072
86. A.J. Grant, P.F. Lalor, and M. Salmi Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease Lancet 359 2002 150 157
87. M. Salmi, K. Kalimo, and S. Jalkanen Induction and function of vascular adhesion protein-1 at sites of inflammation J Exp Med 178 1993 2255 2260
88. E. Liaskou, M. Karikoski, and G.M. Reynolds Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity Hepatology 53 2011 661 672
89. B. Eksteen, J.R. Mora, and E.L. Haughton Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells Gastroenterology 137 2009 320 329
90. B. Xu, U. Broome, and B.G. Ericzon High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6 Gut 51 2002 120 127
91. A. Karrar, U. Broome, and T. Sodergren Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis Gastroenterology 132 2007 1504 1514
92. M. Kekilli, B. Tunc, and Y. Beyazit Circulating CD4+CD25+ regulatory T cells in the pathobiology of ulcerative colitis and concurrent primary sclerosing cholangitis Dig Dis Sci 58 2013 1250 1255
93. T. Korn, E. Bettelli, and M. Oukka IL-17 and Th17 cells Annu Rev Immunol 27 2009 485 517
94. R.P. Oude Elferink, and C.C. Paulusma Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein) Pflugers Arch 453 2007 601 610
95. M. Trauner, P. Fickert, and M. Wagner MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes Semin Liver Dis 27 2007 77 98
96. I. Durieu, O. Pellet, and L. Simonot Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study J Hepatol 30 1999 1052 1056
97. S. Sheth, J.C. Shea, and M.D. Bishop Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis Hum Genet 113 2003 286 292
98. K. Takeda, Y. Kojima, and K. Ikejima Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease Proc Natl Acad Sci U S A 105 2008 10895 10900
99. K.D. Lindor Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group N Engl J Med 336 1997 691 695
100. S.A. Mitchell, D.S. Bansi, and N. Hunt A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 2001 900 907
101. D.M. Harnois, P. Angulo, and R.A. Jorgensen High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol 96 2001 1558 1562
102. R. Olsson, K.M. Boberg, and O.S. de Muckadell High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study Gastroenterology 129 2005 1464 1472
103. K.D. Lindor, K.V. Kowdley, and V.A. Luketic High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 2009 808 814
104. M.H. Imam, E. Sinakos, and A.A. Gossard High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis Aliment Pharmacol Ther 34 2011 1185 1192
105. J.E. Eaton, M.G. Silveira, and D.S. Pardi High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Am J Gastroenterol 106 2011 1638 1645
106. C.K. Triantos, N.M. Koukias, and V.N. Nikolopoulou Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis Aliment Pharmacol Ther 34 2011 901 910
107. EASL clinical practice guidelines: management of cholestatic liver diseases J Hepatol 51 2009 237 267
108. D.W. Hommes, W. Erkelens, and C. Ponsioen A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis J Clin Gastroenterol 42 2008 522 526
109. S.N. Cullen, and R.W. Chapman Review article: current management of primary sclerosing cholangitis Aliment Pharmacol Ther 21 2005 933 948
110. M.P. Manns, M. Woynarowski, and W. Kreisel Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis Gastroenterology 139 2010 1198 1206
111. A. Stiehl, G. Rudolph, and P. Kloters-Plachky Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment J Hepatol 36 2002 151 156
112. M. Kaya, B.T. Petersen, and P. Angulo Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis Am J Gastroenterol 96 2001 1059 1066
113. A.A. Alkhatib, K. Hilden, and D.G. Adler Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective Dig Dis Sci 56 2011 3685 3688
114. S. Ismail, L. Kylanpaa, and H. Mustonen Risk factors for complications of ERCP in primary sclerosing cholangitis Endoscopy 44 2012 1133 1138
115. K. Bjoro, B. Brandsaeter, and A. Foss Liver transplantation in primary sclerosing cholangitis Semin Liver Dis 26 2006 69 79
116. I.W. Graziadei, R.H. Wiesner, and P.J. Marotta Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis Hepatology 30 1999 1121 1127
117. F.K. Welsh, and S.J. Wigmore Roux-en-Y choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis Transplantation 77 2004 602 604
118. D.S. Goldberg, B. French, and A. Thomasson Current trends in living donor liver transplantation for primary sclerosing cholangitis Transplantation 91 2011 1148 1152
119. D.S. Goldberg, A. Camp, and A. Martinez-Camacho Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis Liver Transpl 19 2013 250 258
120. S. Darwish Murad, W.R. Kim, and D.M. Harnois Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers Gastroenterology 143 2012 88 98.e3 quiz e14
121. I.W. Graziadei, R.H. Wiesner, and K.P. Batts Recurrence of primary sclerosing cholangitis following liver transplantation Hepatology 29 1999 1050 1056
122. B. Fosby, T.H. Karlsen, and E. Melum Recurrence and rejection in liver transplantation for primary sclerosing cholangitis World J Gastroenterol 18 2012 1 15
123. O. Adeyi, S.E. Fischer, and M. Guindi Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation J Clin Pathol 63 2010 47 74
124. A. Bergquist, A. Ekbom, and R. Olsson Hepatic and extrahepatic malignancies in primary sclerosing cholangitis J Hepatol 36 2002 321 327
125. J. Fevery, C. Verslype, and G. Lai Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis Dig Dis Sci 52 2007 3123 3135
126. U. Broome, R. Lofberg, and B. Veress Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential Hepatology 22 1995 1404 1408
127. K.M. Boberg, A. Bergquist, and S. Mitchell Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation Scand J Gastroenterol 37 2002 1205 1211
128. N. Razumilava, G.J. Gores, and K.D. Lindor Cancer surveillance in patients with primary sclerosing cholangitis Hepatology 54 2011 1842 1852
129. C. Levy, J. Lymp, and P. Angulo The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis Dig Dis Sci 50 2005 1734 1740
130. B.R. Kipp, L.M. Stadheim, and S.A. Halling A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures Am J Gastroenterol 99 2004 1675 1681
131. S.Y. Bangarulingam, E. Bjornsson, and F. Enders Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis Hepatology 51 2010 174 180
132. E.G. Barr Fritcher, B.R. Kipp, and J.S. Voss Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma Am J Gastroenterol 106 2011 2023 2028
133. N.S. Sandanayake, J. Sinclair, and F. Andreola A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures Br J Cancer 105 2011 1370 1378
134. T.O. Lankisch, J. Metzger, and A.A. Negm Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis Hepatology 53 2011 875 884
135. J. Metzger, A.A. Negm, and R.R. Plentz Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders Gut 62 2013 122 130
136. D.J. Brandt, R.L. MacCarty, and J.W. Charboneau Gallbladder disease in patients with primary sclerosing cholangitis Am J Roentgenol 150 1988 571 574
137. D.C. Buckles, K.D. Lindor, and N.F. Larusso In primary sclerosing cholangitis, gallbladder polyps are frequently malignant Am J Gastroenterol 97 2002 1138 1142
138. J.E. Eaton, E.W. Thackeray, and K.D. Lindor Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis Am J Gastroenterol 107 2012 431 439
139. L. Lindstrom, A. Lapidus, and A. Ost Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis Dis Colon Rectum 54 2011 1392 1397
140. E.W. Thackeray, P. Charatcharoenwitthaya, and D. Elfaki Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis Clin Gastroenterol Hepatol 9 2011 52 56
141. M. Walker, and S. Radley Adenocarcinoma in an ileoanal pouch formed for ulcerative colitis in a patient with primary sclerosing cholangitis and a liver transplant: report of a case and review of the literature Dis Colon Rectum 49 2006 909 912
142. S.R. Cairns, J.H. Scholefield, and R.J. Steele Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) Gut 59 2010 666 689
143. F.A. Farraye, R.D. Odze, and J. Eaden AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease Gastroenterology 138 2010 746 774 774 e1-4; quiz e12-13
144. M. Vieth, H. Behrens, and M. Stolte Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment Gut 55 2006 1151 1155
145. B.Y. Tung, M.J. Emond, and R.C. Haggitt Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Ann Intern Med 134 2001 89 95
146. D.S. Pardi, E.V. Loftus Jr., and W.K. Kremers Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 2003 889 893
147. J.M. Wolf, L.A. Rybicki, and B.A. Lashner The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis Aliment Pharmacol Ther 22 2005 783 788
148. L. Lindstrom, K.M. Boberg, and O. Wikman High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia Aliment Pharmacol Ther 35 2012 451 457
149. K.K. Jorgensen, L. Lindstrom, and M. Cvancarova Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study Scand J Gastroenterol 8-9 2012 1021 1029
150. M.P. Epstein, and M.M. Kaplan A pilot study of etanercept in the treatment of primary sclerosing cholangitis Dig Dis Sci 49 2004 1 4
151. W.J. Sandborn, C. Gasink, and L.L. Gao Ustekinumab induction and maintenance therapy in refractory Crohn's disease N Engl J Med 367 2012 1519 1528
152. A. Parikh, T. Leach, and T. Wyant Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study Inflamm Bowel Dis 18 2012 1470 1479
153. M.M. Seavey, and P. Dobrzanski The many faces of Janus kinase Biochem Pharmacol 83 2012 1136 1145
154. W.J. Sandborn, S. Ghosh, and J. Panes Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis N Engl J Med 367 2012 616 624
155. K. Ghoreschi, M.I. Jesson, and X. Li Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) J Immunol 186 2011 4234 4243
156. D.M. Meyer, M.I. Jesson, and X. Li Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis J Inflamm 7 2010 41
157. J.H. Distler, and O. Distler Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies Ann Rheum Dis 69 Suppl 1 2010 i48 i51
158. H. Yoshiji, R. Noguchi, and S. Kuriyama Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats Am J Physiol Gastrointest Liver Physiol 288 2005 G907 G913
159. C. Seidel, M. Fenner, and F. Langer Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST) BMC Cancer 12 2012 186
160. D.C. Rockey Current and future anti-fibrotic therapies for chronic liver disease Clin Liver Dis 12 2008 939 962 xi
161. S.K. Satapathy, P. Sakhuja, and V. Malhotra Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis J Gastroenterol Hepatol 22 2007 634 638
162. A.E. Bharucha, R. Jorgensen, and S.N. Lichtman A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis Am J Gastroenterol 95 2000 2338 2342
163. R. Olsson, U. Broome, and A. Danielsson Colchicine treatment of primary sclerosing cholangitis Gastroenterology 108 1995 1199 1203
164. H. He, A. Mennone, and J.L. Boyer Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells Hepatology 53 2011 548 557
165. K.D. Lindor Farnesoid X receptor agonists for primary biliary cirrhosis Curr Opin Gastroenterol 27 2011 285 288
166. R. Poupon Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action Clin Res Hepatol Gastroenterol 36 Suppl 1 2012 S3 S12
167. E. Halilbasic, R. Fiorotto, and P. Fickert Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice Hepatology 49 2009 1972 1981
168. P. Fickert, M. Wagner, and H.U. Marschall 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice Gastroenterology 130 2006 465 481
169. S. Al Mamari, J. Djordjevic, and J.S. Halliday Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis J Hepatol 58 2013 329 334